These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 8285633

  • 21. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H, El Amin N, Davies T, Appelbaum PC, Edlund C.
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [Abstract] [Full Text] [Related]

  • 22. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
    King A, Bethune L, Phillips I.
    J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
    [Abstract] [Full Text] [Related]

  • 23. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A, Hardardottir H, Bottolfsen KL.
    Chemotherapy; 1991 Jun; 37(2):98-105. PubMed ID: 2032475
    [Abstract] [Full Text] [Related]

  • 24. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
    Nye K, Shi YG, Andrews JM, Ashby JP, Wise R.
    J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
    [Abstract] [Full Text] [Related]

  • 25. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
    Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC.
    Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
    [Abstract] [Full Text] [Related]

  • 26. Temafloxacin: an overview.
    Pankey GA.
    Am J Med; 1991 Dec 30; 91(6A):166S-172S. PubMed ID: 1662889
    [Abstract] [Full Text] [Related]

  • 27. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A, Bethune L, Phillips I.
    J Antimicrob Chemother; 1991 Nov 30; 28(5):719-25. PubMed ID: 1663930
    [Abstract] [Full Text] [Related]

  • 28. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC.
    Am J Med; 1991 Dec 30; 91(6A):15S-18S. PubMed ID: 1662886
    [Abstract] [Full Text] [Related]

  • 29. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
    Spangler SK, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1997 Jun 30; 39 Suppl B():23-7. PubMed ID: 9222066
    [Abstract] [Full Text] [Related]

  • 30. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
    Goldstein EJ.
    Clin Infect Dis; 1993 Jun 30; 16 Suppl 4():S377-81. PubMed ID: 8324151
    [Abstract] [Full Text] [Related]

  • 31. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
    Mahr G, Sörgel F, Granneman GR, Kinzig M, Muth P, Patterson K, Fuhr U, Nickel P, Stephan U.
    Clin Pharmacokinet; 1992 Jun 30; 22 Suppl 1():90-7. PubMed ID: 1319876
    [Abstract] [Full Text] [Related]

  • 32. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Drugs Exp Clin Res; 1992 Jun 30; 18(8):311-7. PubMed ID: 1338041
    [Abstract] [Full Text] [Related]

  • 33. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1994 Sep 30; 38(9):2065-72. PubMed ID: 7811020
    [Abstract] [Full Text] [Related]

  • 34. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
    Barry AL, Fuchs PC.
    J Antimicrob Chemother; 1991 Nov 30; 28(5):695-9. PubMed ID: 1663929
    [Abstract] [Full Text] [Related]

  • 35. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ, Citron DM.
    J Clin Microbiol; 1988 Nov 30; 26(11):2361-6. PubMed ID: 3235664
    [Abstract] [Full Text] [Related]

  • 36. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM, Molitoris E, Finegold SM.
    Antimicrob Agents Chemother; 1993 Nov 30; 37(11):2509-13. PubMed ID: 8285647
    [Abstract] [Full Text] [Related]

  • 37. Killing kinetics of four quinolones against gram-positive cocci.
    Cantón E, Ramon MS, Jimenez MT, Martinez JP.
    Chemotherapy; 1993 Nov 30; 39(6):394-9. PubMed ID: 8222866
    [Abstract] [Full Text] [Related]

  • 38. Activity of temafloxacin against respiratory pathogens.
    Swanson RN, Hardy DJ, Chu DT, Shipkowitz NL, Clement JJ.
    Antimicrob Agents Chemother; 1991 Mar 30; 35(3):423-9. PubMed ID: 2039192
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM, Molitoris E, Reeves D, Finegold SM.
    Antimicrob Agents Chemother; 1994 Oct 30; 38(10):2504-9. PubMed ID: 7840599
    [Abstract] [Full Text] [Related]

  • 40. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
    Aldridge KE, Stratton CW.
    J Antimicrob Chemother; 1991 Nov 30; 28(5):701-5. PubMed ID: 1778873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.